Promising Growth Forecasts Leading to Analysts’ Optimism for Procept Biorobotics (PRCT)

Procept Biorobotics Corp. (NASDAQ:PRCT) is one of the most promising mid-cap healthcare stocks under $50.

On December 12, UBS analyst Danielle Antalffy initiated coverage with a bullish rating on Procept Biorobotics Corp. (NASDAQ:PRCT). She rated the stock as a Buy and estimated a target price of $62. This leads to an upside potential of over 93% from current levels.

VILevi/Shutterstock.com

Antalffy’s rating is backed by her view of the company’s promising growth prospects, which will be driven by the management’s ambitions to raise the utilization of their current installed base and also their greenfield undertakings going forward. She anticipates the company to turn profitable by 2027, given the expected expansion of topline and gross margins, as well as operational efficiencies that will drive costs down.

The broader analyst coverage also indicates a highly optimistic view of Procept Biorobotics Corp. (NASDAQ:PRCT). As of December 19 closing, there were 10 analyst ratings assigned to the stock, of which 80% were Buy calls, and the remaining 20% were Hold ratings. With no Sell rating, analysts remain bullish on the stock and have set a 1-year average price target of $51.75. Hence, the stock offers over 61% upside potential after a bearish run in 2025.

Procept Biorobotics Corp. (NASDAQ:PRCT) is a surgical robotics company focusing on robotic treatments for male urological health. Through their flagship offering, Aquablation® therapy, they amalgamate technology and medical advancements to offer personalized care and improved health for men. The company is committed to revolutionizing benign prostatic hyperplasia (BPH) treatments.

READ NEXT:  Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy and 30 Most Fantastic Stocks Every Investor Should Pay Attention To.

Disclosure: None. This article is originally published at Insider Monkey.